Here are a couple of additional installments from our special two hour webinar on molecular markers in advanced NSCLC, broadcast from the Santa Monica Targeted Therapies in Lung Cancer conference and featuring four great panelists who joined me that day:
- Drs. Charlie Rudin, Johns Hopkins University
- Dr. Alice Shaw, Massachusetts General Hospital
- Dr. David Spigel, Sarah Cannon Cancer Center
- Dr. Glen Goss, University of Ottawa, and head of NCI-Canada’s Lung Cancer Committee
Part three of our program includes some debate on the merits of uniform vs. more selective testing of “druggable” targets, as well as a discussion of whether to favor simultaneous testing for molecular targets vs. a sequential, stepwise approach (because the key relevant targets are mutually exclusive). We also review the challenge of delays in treatment that can emerge as a byproduct of weeks of up front testing.
Below you’ll find the audio and video versions of the podcast, along with the transcript and figures for this activity.
Molecular Targets PD Pt 3 Video Podcast
Molecular Targets PD Pt 3 Audio Podcast
Molecular Targets PD Pt 3 Transcript
